SKLB610 is primarily investigated for its potential therapeutic applications in cancer treatment. It functions as a kinase inhibitor, targeting specific enzymes involved in cell proliferation and survival. Research suggests it may be effective in inhibiting tumor growth by disrupting signaling pathways that promote cancer cell development. Its application is particularly studied in the context of lung cancer, where it shows promise in preclinical models. Additionally, SKLB610 is being explored for its ability to enhance the efficacy of other anticancer therapies when used in combination treatments. Further studies are ongoing to evaluate its safety, pharmacokinetics, and potential clinical benefits.